Emerging protein kinase inhibitors for the treatment of multiple myeloma

References

• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298:1912–1934.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26–48.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Cancer Netw. 2018;16:11–20.
   PubMed Web of Science ®Google Scholar
• Rask-Andersen M, Masuram S, Schiöth HB. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2013;54:9–26.
   PubMed Web of Science ®Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–1737.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134.
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett. 2006;233:10–15.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–2238.
   PubMed Web of Science ®Google Scholar
• Chell V, Balmanno K, Little AS, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2013;32:3059–3070.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–598.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520–1529.
   PubMed Web of Science ®Google Scholar
• Wildes TM, Procknow E, Gao F, et al. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma. 2009;50:137–140.
   PubMed Web of Science ®Google Scholar
• Facon T, Leleu X, Stewart AK, et al. Dasatinib in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I study. Blood. 2009;114:1876.
   Google Scholar
• Trudel S, Bergsagel PL, Singhal S, et al. A phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) antibody, in patients with relapsed or refractory t(4;14)-positive multiple myeloma. Blood. 2012;120:4029.
   Web of Science ®Google Scholar
• Smith DC, Britten C, Garon EB, et al. A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. J Clin Oncol. 2017;28:3105.
   Google Scholar
• Dispenzieri A, Gertz MA, Lacy MQ, et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma. 2006;47:39–42.
   PubMed Web of Science ®Google Scholar
• Lendvai N, Yee AJ, Tsakos I, et al. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016;127:2355–2356.
   PubMed Web of Science ®Google Scholar
• Richardson P, Lonial S, Jakubowiak A, et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood. 2007;110:1164.
   Web of Science ®Google Scholar
• Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011;29:4243–4249.
   PubMed Web of Science ®Google Scholar
• Spencer A, Yoon -S-S, Harrison SJ, et al. Novel AKT Inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Preliminary results from a phase I first-time-in-human study. Blood. 2011;118:1856.
   Web of Science ®Google Scholar
• Yee AJ, Mahindra AK, Richardson PG, et al. Biomarker correlation with outcomes in patients with relapsed or refractory multiple Myeloma on a phase I study of everolimus in combination with lenalidomide. Blood. 2011;118:3966.
   Web of Science ®Google Scholar
• Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple Myeloma: evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein. J Clin Oncol. 2011;29:3427–3434.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Siegel D, Vij R, et al. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia. Am J Hematol. 2016 Jun;91(4):400–405.
   PubMed Web of Science ®Google Scholar
• Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2018;59:2588–2594.
   PubMed Web of Science ®Google Scholar
• Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. 2011;17:3388–3397.
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Poi M, Bowers MA, et al. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol. 2014;73:249–257.
   PubMed Web of Science ®Google Scholar
• Tong W-G, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010;28:3015–3022.
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Berdeja JG, Vesole DH, et al. TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients. Blood. 2015;126:3052.
   Web of Science ®Google Scholar
• Roschewski M, Farooqui M, Aue G, et al. Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia. 2013;27:1920–1923.
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Kumar S, Hofmeister C, et al. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. Br J Haematol. 2016;174:323–325.
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383–1395.
   PubMed Web of Science ®Google Scholar
• Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004;34:235–239.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Siegel DS, Vij R, et al. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia. Am J Hematol. 2016;91:400–405.
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004;10:88–95.
   PubMed Web of Science ®Google Scholar
• Kropff M, Kienast J, Bisping G, et al. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Anticancer Res. 2009;29:4233–4238.
   PubMed Web of Science ®Google Scholar
• Vij R, Ansstas G, Mosley JC, et al. Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2010;51:1577–1579.
   PubMed Web of Science ®Google Scholar
• Scheid C, Reece D, Beksac M, et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015;95:316–324.
   PubMed Web of Science ®Google Scholar
• Prince HM, Hönemann D, Spencer A, et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A phase 2 study of pazopanib (GW786034). Blood. 2009;113:4819–4820.
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma–NCIC CTG IND.145. Invest New Drugs. 2006;24:529–535.
   PubMed Web of Science ®Google Scholar
• Kumar S, Flynn PJ, Chng WJJ, et al. A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma. Blood. 2009;114:4954.
   PubMedGoogle Scholar
• Srkalovic G, Hussein MA, Hoering A, et al. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med. 2014;3:1275–1283.
   PubMed Web of Science ®Google Scholar
• Yordanova A, Hose D, Neben K, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol. 2013;31:197–200.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Jett J, Marks R, et al. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013;31:1201–1206.
   PubMed Web of Science ®Google Scholar
• Gambella M, Palumbo A, Rocci A. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy? Expert Rev Mol Diagn. 2015;15:881–893.
   PubMed Web of Science ®Google Scholar
• Mahtouk K, Tjin EPM, Spaargaren M, et al. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta. 2010;1806:208–219.
   PubMed Web of Science ®Google Scholar
• Lath DL, Buckle CH, Evans HR, et al. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS One. 2018;13:e0199517.
   PubMed Web of Science ®Google Scholar
• Baljevic M, Zaman S, Baladandayuthapani V, et al. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017;96:977–985.
   PubMed Web of Science ®Google Scholar
• Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113:4614–4626.
   PubMed Web of Science ®Google Scholar
• Sprynski AC, Hose D, Kassambara A, et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia. 2010;24:1940–1950.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008;26:3196–3203.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Embo J. 1986;5:2503–2512.
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol. 2006;6:620–625.
   PubMed Web of Science ®Google Scholar
• Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791.
   PubMed Web of Science ®Google Scholar
• Podar K, Raje N, Anderson KC. Inhibition of the TGF-beta signaling pathway in tumor cells. Recent Results Cancer Res. 2007;172:77–97.
   PubMedGoogle Scholar
• Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood. 1996;87:1928–1938.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98:2992–2998.
   PubMed Web of Science ®Google Scholar
• Otsuki T, Yamada O, Kurebayashi J, et al. Expression and In VitroModification of Parathyroid Hormone-Related Protein (PTHrP) and PTH/PTHrP-Receptor in Human Myeloma Cells. Leuk Lymphoma. 2001;41:397–409.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Abe M, Hiasa M, et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010;5:e9870.
   PubMed Web of Science ®Google Scholar
• de Weers M, Mensink RG, Kraakman ME, et al. Mutation analysis of the Bruton’s tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum Mol Genet. 1994;3:161–166.
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong Y, Jiang Q-L, et al. Bruton’s tyrosine kinase: potential target in human multiple myeloma. Leuk Lymphoma. 2014;55:177–181.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Anderson KC. Bruton’s tyrosine kinase: oncotarget in myeloma. Oncotarget. 2012;3:913–914.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Roy AN, et al. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. Br J Haematol. 2018;181:628–636.
   PubMed Web of Science ®Google Scholar
• Eda H, Santo L, Cirstea DD, et al. A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 2014;28:1892–1901.
   PubMed Web of Science ®Google Scholar
• Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573–581.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95–98.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Faderl S, Ravandi F, et al. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006;6:671–679.
   PubMed Web of Science ®Google Scholar
• Podar K, Hideshima T, Chauhan D, et al. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets. 2005;9:359–381.
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol. 2003;162:1449–1461.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Podar K, Harousseau J-L, et al. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004;3:1259–1262.
   PubMed Web of Science ®Google Scholar
• Swords R, Kelly K, Carew J, et al. The Pim kinases: new targets for drug development. Curr Drug Targets. 2011;12:2059–2066.
   PubMed Web of Science ®Google Scholar
• Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 2013;122:1610–1620.
   PubMed Web of Science ®Google Scholar
• Keane NA, Reidy M, Natoni A, et al. Targeting the Pim kinases in multiple myeloma. Blood Cancer J. 2015;5:e325.
   PubMed Web of Science ®Google Scholar
• Raab MS, Thomas SK, Ocio EM, et al. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2019. Epub ahead of print
   Google Scholar
• Manni S, Carrino M, Semenzato G, et al. Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance. Int J Mol Sci. 2018;19:E1512.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–348.
   PubMed Web of Science ®Google Scholar
• Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004;103:3271–3277.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discov. 2013;3:862–869.
   Google Scholar
• Sharman JP, Chmielecki J, Morosini D, et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:e161–3.
   PubMedGoogle Scholar
• Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–435.
   PubMed Web of Science ®Google Scholar
• Heuck C, Jethava Y, Khan RZ, et al. Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. Blood. 2014;124:4775.
   Web of Science ®Google Scholar
• Mey UJM, Renner C, von Moos R. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation. Hematol Oncol. 2017;35:890–893.
   PubMed Web of Science ®Google Scholar
• Holkova B, Zingone A, Kmieciak M, et al. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016;22:1067–1075.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373:726–736.
   PubMed Web of Science ®Google Scholar
• Keane NA, S V G, Krawczyk J, et al. AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets. 2014;18:897–915.
   PubMed Web of Science ®Google Scholar
• Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood. 2000;96:3560–3568.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991–6000.
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956–1967.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Kimlinger T, Haug J, et al. Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway. PLoS One. 2012;7:e50005.
   PubMed Web of Science ®Google Scholar
• Balasis ME, Forinash KD, Chen YA, et al. Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice. Clin Cancer Res. 2011;17:2852–2862.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Richardson PG, Zimmerman T, et al. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012;158:472–480.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Eng C, Kolesar J, et al. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012;8:623–633.
   PubMed Web of Science ®Google Scholar
• Mimura N, Hideshima T, Shimomura T, et al. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014;74:4458–4469.
   PubMed Web of Science ®Google Scholar
• Song IS, Jeong YJ, Jeong SH, et al. Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma. Cancer Lett. 2018;432:205–215.
   PubMed Web of Science ®Google Scholar
• Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124:2190–2195.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Patnaik A, Papadopoulos KP, et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol. 2015;75:183–189.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122–1128.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. MTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Li J, Zhu J, Cao B, et al. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr Pharm Des. 2014;20:125–135.
   PubMed Web of Science ®Google Scholar
• Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004;104:4181–4187.
   PubMed Web of Science ®Google Scholar
• Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res. 2009;33:1475–1480.
   PubMed Web of Science ®Google Scholar
• Günther A, Baumann P, Burger R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100:541–547.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Weller E, Vij R, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011;12:263–272.
   PubMed Web of Science ®Google Scholar
• Yee AJ, Hari P, Marcheselli R, et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014;166:401–409.
   PubMed Web of Science ®Google Scholar
• Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood. 2010;116:4560–4568.
   PubMed Web of Science ®Google Scholar
• Cirstea D, Santo L, Hideshima T, et al. Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Mol Cancer Ther. 2014;13:2489–2500.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Kelley RK, Shih KC, et al. A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015;121:3481–3490.
   PubMed Web of Science ®Google Scholar
• Yang C, Huang X, Liu H, et al. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget. 2017;8:39185–39197.
   PubMedGoogle Scholar
• Swords R, Mahalingam D, O’Dwyer M, et al. Cdc7 kinase - a new target for drug development. Eur J Cancer. 2010;46:33–40.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Lacy MQ, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: A phase 2 trial with clinical and pharmacodynamic end-points. Haematologica. 2006;91:390–393.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Badros AZ, Costa LJ, et al. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56:3320–3328.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant B, Chng WJ, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015;125:443–448.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Tiedemann R, Shi C-X, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011;117:3847–3857.
   PubMed Web of Science ®Google Scholar
• Hari PN, Landau H, Richardson PG, et al. A phase I/II open-label multicenter study of the cyclin kinase inhibitor AT7519M alone and in combination with bortezomib in patients with previously treated multiple myeloma. Blood. 2013;122:1976.
   Web of Science ®Google Scholar
• Raje N, Hideshima T, Mukherjee S, et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009;23:961–970.
   PubMed Web of Science ®Google Scholar
• Alvarez-Fernandez S, Ortiz-Ruiz MJ, Parrott T, et al. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res. 2013;19:2677–2687.
   PubMed Web of Science ®Google Scholar
• Cirstea D, Hideshima T, Santo L, et al. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013;27:2366–2375.
   PubMed Web of Science ®Google Scholar
• McMillin DW, Delmore J, Negri J, et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011;152:420–432.
   PubMed Web of Science ®Google Scholar
• Natoni A, Coyne MRE, Jacobsen A, et al. Characterization of a dual CDC7/CDK9 inhibitor in multiple myeloma cellular models. Cancers (Basel). 2013;5:901–918.
   PubMedGoogle Scholar
• Liu H-Y, Tuckett AZ, Fennell M, et al. Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation. Invest New Drugs. 2018;36:590–600.
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Bargiotti A, Berthelsen J, et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009;52:293–307.
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842–854.
   PubMed Web of Science ®Google Scholar
• Brown JR, Koretke KK, Birkeland ML, et al. Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. BMC Evol Biol. 2004;4:39.
   PubMed Web of Science ®Google Scholar
• Kollareddy M, Dzubak P, Zheleva D, et al. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:27–33.
   PubMed Web of Science ®Google Scholar
• Malumbres M. Physiological Relevance of Cell Cycle Kinases. Physiol Rev. 2011;91:973–1007.
   PubMed Web of Science ®Google Scholar
• Craig SN, Wyatt MD, McInnes C. Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014;9:773–789.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639–1648.
   PubMed Web of Science ®Google Scholar
• Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol. 2011;155:561–579.
   PubMed Web of Science ®Google Scholar
• Maes A, Menu E, De Veirman K, et al. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget. 2017;8:90501–90520.
   PubMedGoogle Scholar
• Stewart HJ, Kishikova L, Powell FL, et al. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Exp Hematol. 2011;39:330–338.
   PubMed Web of Science ®Google Scholar
• Evans RP, Dueck G, Sidhu R, et al. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Leuk Res. 2011;35:1637–1643.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang Z, Liu Z. Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells. Tumor Biol. 2013;34:2241–2247.
   PubMedGoogle Scholar
• Hay AE, Murugesan A, DiPasquale AM, et al. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk Lymphoma. 2016;57:1463–1466.
   PubMed Web of Science ®Google Scholar
• Ganguly R, Hong CS, Smith LGF, et al. Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther. 2014;13:1393–1398.
   PubMed Web of Science ®Google Scholar
• Muller J, Bolomsky A, Dubois S, et al. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease. Haematologica. 2018;103:1359–1368.
   PubMed Web of Science ®Google Scholar
• Podar K, Raab MS, Chauhan D, et al. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs. 2007;16:1693–1707.
   PubMed Web of Science ®Google Scholar
• Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007;109:1669–1677.
   PubMed Web of Science ®Google Scholar
• Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008;49:1374–1383.
   PubMed Web of Science ®Google Scholar
• Jourdan E, Leblond V, Maisonneuve H, et al. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. Leuk Lymphoma. 2014;55:2013–2017.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Munshi NC, Harris BN, et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011;86:573–578.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101:703–705.
   PubMed Web of Science ®Google Scholar
• He J, Liu Z, Zheng Y, et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012;72:6393–6402.
   PubMed Web of Science ®Google Scholar
• Liu H, He J, Yang J. Tumor cell p38 MAPK: A trigger of cancer bone osteolysis. Cancer Cell Microenviron. 2015;2:e464.
   PubMedGoogle Scholar
• Ishitsuka K, Hideshima T, Neri P, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008;141:598–606.
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Medicherla S, Coulton L, et al. Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007;67:4572–4577.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Ocio EM, Pandiella A, et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008;68:5216–5225.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Krishnan A, Lonial S, et al. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood. 2006;108:3580.
   PubMedGoogle Scholar
• Mateos MV, Cibeira MT, Richardson PG, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010;16:3260–3269.
   PubMed Web of Science ®Google Scholar
• Baumann P, Mandl-Weber S, Emmerich B, et al. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res. 2007;313:3592–3603.
   PubMed Web of Science ®Google Scholar
• Baumann P, Mandl-Weber S, Emmerich B, et al. Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs. 2007;18:405–410.
   PubMed Web of Science ®Google Scholar
• Zi F-M, He J-S, Li Y, et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett. 2015;356:443–453.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J Exp Clin Cancer Res. 2018;37:63.
   PubMed Web of Science ®Google Scholar
• Wu W, Merriman K, Nabaah A, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014;111:628–636.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Lu J, Kusakai G-I, et al. ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol. 2004;24:3526–3535.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Iida S, Kato-Uranishi M, et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene. 2005;24:6936–6944.
   PubMed Web of Science ®Google Scholar
• Perumal D, Kuo P-Y, Leshchenko VV, et al. Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma. Cancer Res. 2016;76:1225–1236.
   PubMed Web of Science ®Google Scholar
• David J-P, Mehic D, Bakiri L, et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest. 2005;115:664–672.
   PubMed Web of Science ®Google Scholar
• Kang S, Elf S, Lythgoe K, et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest. 2010;120:1165–1177.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Yin H, Bruins LA, et al. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood. 2015;125:483–491.
   PubMed Web of Science ®Google Scholar
• Matthews GM, de Matos Simoes R, Dhimolea E, et al. NF-κB dysregulation in multiple myeloma. Semin Cancer Biol. 2016;39:68–76.
   PubMed Web of Science ®Google Scholar
• Piazza F, Manni S, Semenzato G. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3. Leuk Res. 2013;37:221–227.
   PubMed Web of Science ®Google Scholar
• Manni S, Toscani D, Mandato E, et al. Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia. 2014;28:2094–2097.
   PubMed Web of Science ®Google Scholar
• Chon HJ, Bae KJ, Lee Y, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015;6:70.
   PubMed Web of Science ®Google Scholar
• Papaioannou A, Chevet E. Driving cancer tumorigenesis and metastasis through UPR signaling. Curr Top Microbiol Immunol. 2018;414:159–192.
   PubMed Web of Science ®Google Scholar
• Vincenz L, Jager R, O’Dwyer M, et al. Endoplasmic reticulum stress and the unfolded protein response: targeting the achilles heel of multiple myeloma. Mol Cancer Ther. 2013;12:831–843.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Chiosis G. HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011;11:S77–81.
   PubMedGoogle Scholar
• Manni S, Brancalion A, Tubi LQ, et al. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res. 2012;18:1888–1900.
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Zhu YX, Schmidt J, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115:1594–1604.
   PubMed Web of Science ®Google Scholar
• de Boussac H, Bruyer A, Robert N, et al. Kinome expression profiling in multiple myeloma identifies new therapeutic targets. Blood. 2017;130:1766.
   Web of Science ®Google Scholar
• Vikova V, Jourdan M, Robert N, et al. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. Theranostics. 2019;9:540–553.
   PubMed Web of Science ®Google Scholar